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Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is one of the most
frequent cardiovascular diseases among both women and men. Although age-adjusted
AF incidence and prevalence is larger among men, women are older at the time of AF
diagnosis and have larger risk for AF-associated adverse outcomes such as morality
and stroke. Based on evidence from epidemiological studies, elevated body mass index
seems to confer a higher risk of AF among men. However, evidence regarding sex
differences in the association between diabetes mellitus, elevated blood pressure, and
dysglycemia with AF remains conflicting. While men with AF have larger burden of
coronary artery disease, women with AF tend to have a larger prevalence of heart
failure and valvular heart disease. Recently, several women-specific risk factors including
pregnancy and its complications and number of children have been associated with AF.
Earlier age at menopause, despite being a strong marker of adverse cardiometabolic
risk, does not seem to be associated with increased risk of AF. To reduce the AF burden
in both genders, better understanding of the differences between women and men
with regard to AF is central. Large-scale studies are needed to separately investigate
and report on women and men. Besides observations from epidemiological and clinical
studies, to improve our understanding of sexual dimorphism in AF, sufficiently large
genome-wide association studies as well as well-powered Mendelian randomization
studies are essential to shed light on the sex-specific nature of the associations of risk
factors with AF.
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INTRODUCTION
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is one of the most frequent
cardiovascular diseases (CVD) among both women and men. Verification and diagnosis of AF
is based on the electrocardiogram (ECG). The symptoms secondary to AF are broad. Irregular
palpitations, dyspnea on exertion, and sensation of lightheadedness are among the most common
complaints. Other, more general, symptoms include fatigue, weakness or generalized malaise, and
chest discomfort. AF is currently classified as paroxysmal (i.e., AF terminating spontaneously
or with intervention within 7 days of onset), persistent AF (i.e., continuous AF, sustained more
than 7 days), long-standing persistent (i.e., AF lasting for more than 12 months in duration), and
permanent (i.e., AF cases in which any further attempts to restore and/or maintain sinus rhythm is
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stopped based on the joint decision of the patient and the
clinician) (1–3). Besides traditional risk factors; including larger
body mass index (BMI), diabetes mellitus (DM), hypertension,
smoking, and dyslipidemia, diseases of the heart including
history of heart failure (HF), coronary heart disease (CHD),
and valvular heart disease are among the major risk factors
for AF. Recently, several women-specific risk factors including
pregnancy and its complications and number of children have
been associated with AF. Moreover, evidence regarding age of
menopause, a strong marker of adverse cardiometabolic risk, in
relation to increased risk of AF remains inconclusive. This article
provides an overview of the current literature on differences
in the epidemiology of AF between women and men including
incidence, prevalence, traditional cardiovascular risk factors, and
women-specific risk factors. Further, knowledge gaps and areas
for future research are highlight.
INCIDENCE AND PREVALENCE OF ATRIAL
FIBRILLATION
Prevalence AF of in general population increases with advancing
age, from 0.12–0.16% in individuals younger than 49 years to 1.7–
4.0% in those aged 60–70 years and as high as 13.5–17.8% beyond
80 years of age (4, 5).
The age-adjusted prevalence and incidence of AF is lower
among women compared to men (6–8). The Global Burden of
Disease (GBD) reported an estimated age-adjusted prevalence
(per 1,000 person-years) of 373.1 for women and 596.2 for men
which translated to 12.6 million women and 20.9 million men
living with AF globally in 2010. The age-adjusted incidence rates
(per 1,000 person-years) were 59.5 for women and 77.5 for men
globally in 2010. Of note, the GBD reported progressive increases
in overall burden, incidence, prevalence, and AF-associated
mortality between 1990 and 2010 in both women and men.
Although controversial, the mortality associated with AF seems
to be higher in women (6).
Epidemiological studies show a high lifetime risk of AF in
both women and men (4, 9). At age 55 years, the lifetime risk
to develop AF was 22.2% in women and 23.8% in men in the
population-based Rotterdam Study (4).
RISK FACTORS FOR ATRIAL
FIBRILLATION
Traditional Cardiovascular Risk Factors for
Atrial Fibrillation
Evidence from epidemiological studies has shown several
traditional cardiovascular risk factors to be associated with AF in
both women and men, including elevated BMI, DM, high blood
pressure, smoking, and dyslipidemia.
Elevated BMI
Larger BMI is an established risk factor for AF among both
women and men. Obesity has been shown to increase the risk
of developing AF by 49% compared to non-obese individuals
(10). In the large BiomarCaRE Consortium comprising almost
80,000 individuals among whom over 4,000 incident AF cases,
BMI explained the largest proportion of AF risk (around 20%
for overweight and obesity combined) (9). Elevated BMI was
reported to account for up to 18% of risk for incident AF
among women in the Women’s Health Study (WHS) (11).
A body of evidence suggests a stronger association between
BMI and AF among men, compared with women (9, 12).
One standard deviation (SD) increase in BMI was associated
with 11% and 14% greater excess risk for AF among men
compared to women in the large BiomarCaRE Consortium
(9) and in a recent analyses of the prospective Scottish
Heart Health Extended Cohort, respectively (12). Among
women and men from the Framingham Heart Study (FHS)
(13), the Busselton Health Study (14), and the Malmö Diet
and Cancer Study (15) larger BMI or obesity was also a
stronger risk factor for AF in men than in women, albeit
statistically non-significant.
Diabetes Mellitus
Although diabetes is a strong risk factor for CVD, its independent
association with AF is debated (16). Several (15, 17–20), but
not all (21), studies have reported DM as a risk factor for
incident AF. A large meta-analysis of 1,686,097 subjects, among
whom 108,703 cases of AF, estimated an ∼40% greater risk
of AF among diabetics compared to non-diabetic participants.
The investigators reported a smaller effect estimate for the
studies that had adjusted for multiple risk factors compared
to age-adjusted only studies. After adjustment for other
cardiovascular risk factors, the investigators concluded that
the true risk between DM and subsequent risk of AF may
be closer to 25% (17). Recently, the BiomarCaRE Consortium
and the Scottish Heart Health Extended Cohort did not
find an independent association between DM and incident
AF (9, 12).
DM seems to remain a significant but modest risk factor
for development of AF explaining approximately only 2.5–
3% of the burden of AF (15, 17, 22). DM-associated AF
risk was found to be most pronounced in young diabetes
patients in the Danish nationwide registries (18). Moreover,
the DM-associated AF risk seems to be higher with longer
duration of treated diabetes and worse glycemic control (23).
To date, robust evidence regarding sex differences in the
association between DM with AF remains limited. Although in
a recent machine learning aided systematic review and meta-
analysis, diabetic women were 24% more likely to develop
AF than diabetic men (20), other studies have reported
no interaction by sex in the association between DM and
AF (9, 12, 23).
High Blood Pressure
Hypertension is considered as themost importantmodifiable risk
factor for AF (24). Due to its large prevalence in the population,
hypertension accounts for more AF cases than other risk factors.
In the Atherosclerosis Risk in Communities (ARIC) study,
hypertension alone explained about 22% of AF burden (22). In
BiomarCaRE Consortium, elevated blood pressure >140mmHg
explained 13.7% and 14.2% of AF burden in men and women,
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respectively (9). Hypertension exists in 60–80% of patients with
established AF (25). The strength of the association between
systolic blood pressure and AF is similar among women and
men (9, 12, 26). However, hypertension is more prevalent among
women with AF compared to men with AF (27).
Smoking
Smoking is among the major risk factors for development of
AF. The CHARGE-AF consortium reported 1.44 times higher
incident of AF among current smokers compared with non-
smokers (28). Smoking is associated with AF in a dose-response
manner with increasing risk per cigarette-years (29). Although
smoking has shown to carry a higher risk for CHD and stroke in
women (30, 31), this pattern can not be robustly extended toward
AF. Several studies have reported a larger impact of smoking on
AF among women (26), while others have found a stronger effect
among men (15). Overall, the association between smoking and
AF seems to be similar in both sexes (9, 12, 29, 32, 33).
Lipids
Existing evidence regarding the association between blood
lipids and AF is inconsistent. The ARIC study reported high
levels of total and low-density lipoprotein (LDL) cholesterol to
be associated with a lower risk of AF, whereas high-density
lipoprotein (HDL) cholesterol and triglycerides were not related
to AF risk (34). In a meta-analysis of FHS and MESA, low
levels of HDL cholesterol and high levels of triglycerides, but
not LDL or total cholesterol, were associated with the risk of
AF (35). In a large cohort of 28,449 Japanese subjects who
underwent annual health examinations, low HDL cholesterol
level was associated with an increased risk of developing AF,
while high LDL and total cholesterol levels were associated with
increased risk of AF (36). These conflicting results point toward
existence of “cholesterol paradox” in AF (37). Sex differences
in the relationship between lipid profile and AF have not been
consistently reported by studies. In the large Japanese annual
health examination study, low HDL cholesterol was associated
with an increased risk of new-onset AF only in women, but not
in men (36). In the BiomarCARE Consortium, total cholesterol
was inversely associated with incident AF with a stronger risk
reduction in women. The population attributable risk for total
cholesterol was 8.6% in women and 3.8% in men (9).
Cardiac Diseases as Risk Factors for Atrial
Fibrillation
Heart Failure
HF and AF share common risk factors. Moreover, the two
conditions co-exist (26) and predispose to each other (38). In
epidemiological studies, presence of HF led to 3.37-fold risk of
AF in the Manitoba Follow-Up Study and 2.67-fold risk of AF
in the Cardiovascular Health Study (39, 40). Data on differences
between women and men regarding the association of HF with
AF are scarce. In FHS, HF was associated with 4.5-fold risk of AF
in men and 5.9-fold in woman (26). In the RICA HF registry, AF
was more common among women with HF compared to men
(41). However, in an observational study from the national HF
referral center in Vienna, AF was more frequent amongmen with
HF with preserved ejection fraction (HFpEF) compared with
women (68.4% in men and 54.7% in women) (42). Of note, the
temporal relationship between HF and AF has been investigated
in multiple studies since HF can be an outcome of AF.
Coronary Heart Disease
The relationship between AF and myocardial infarction (MI) is
also bidirectional. CHD has been associated with an increased
risk of AF (43), but AF has also been associated with increased
risk of MI (44). Women with AF have a lower prevalence of
CHD than men with AF (8, 45). Among individuals with AF,
SAFETY investigators reported a prevalence of coronary artery
disease of 24.8% for women vs. 41.4% for men (45). MI overall
is considered to have a stronger association with AF among men.
In FHS, MI increased the risk of AF by 40% among men but not
women (26). In the recent BiomarCARE Consortium, history of
MI increased the risk of AF by 78% in women and by 93% inmen.
The difference between women and men was not statistically
significant. The investigators reported that 3.0% of AF burden in
women and 6.1% of AF burden in men was attributed to history
of MI (9).
Valvular Heart Disease
Women with AF have higher prevalence of valvular heart disease
than men with AF (8, 46). In FHS, valvular heart disease was a
significantly more potent risk factor for AF in women than in
men (odds ratio for the association of vavular heart disease with
AF was 3.4 in women vs. 1.8 in men) (26). Consequently, the
attributable risk from valvular heart disease was ∼3-fold higher
in women than men (18% vs. 5%) (26).
Women-Specific Risk Factors for Atrial
Fibrillation
Pregnancy
Observational studies suggest that pregnancy, in general,
may potentiate supraventricular tachycardias (47). However,
prevalence of AF among pregnant women is very rare (48).
Older age at pregnancy is a risk factor for AF during pregnancy
and AF is more common during the third trimester compared
to the first trimester (48). 1.3% of pregnant women with
structural heart disease suffer AF or atrial flutter during their
pregnancy with a peak at the end of the second trimester.
Experiencing AF or flutter during pregnancy among these
patients is associated with unfavorable maternal outcome
and affects fetal birth weight (49). AF may also occur
during the peripartum period mainly due to drugs used
for tocolysis (50, 51) or as a manifestation of peripartum
cardiomyopathy (52).
Hypertensive Disorders of Pregnancy
Among women with preeclampsia, several electrical and electro-
mechanical changes have been observed including increase in P
wave duration and dispersion and in atrial electro-mechanical
coupling interval measured by tissue Doppler (53). These
changes are well-known markers for increased AF incidence
in normal hearts. It is yet unclear whether these alterations
occur, in general, during pregnancy or they happen only during
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abnormal pregnancy due to the vascular/atrial susceptibility.
A recent nested case-control study from Olmsted County,
Minnesota, reported women with AF to be more likely to have
experienced a hypertensive pregnancy disorder. This relationship
was at least partially mediated by associated obesity and
hypertension (54).
Number of Children
Among 34,639 women from the WHS, women who had four
or more pregnancies were 30–50% more likely to develop AF
later in life than women with no pregnancies (55). Repeated
exposure to physiological, metabolic, or hormonal factors
during pregnancy could, at least partly, explain the increased
AF risk.
Menopause
Earlier age at menopausal is considered a strong marker of
adverse cardiometabolic risk and has been associated with
increased risk of CVD and cardiovascular mortality. However,
epidemiological studies so far have failed to show an association
between age at natural menopause and increased risk of AF.
The large WHS including over 30,000 women with 1,350 cases
of new-onset AF during a median follow-up of 20.5 years,
reported no association between earlier age of menopause
with risk of AF (compared with age of menopause >54 years
as the referent, hazard ratios (HR) for age of menopause:
<45 years: 0.82; 45–49 years: 0.90; 50–54 years: 0.89—all
statistically non-significant) (56). This is in line with a previous
report by the FHS investigators regarding no association
between menopausal age with incident AF (HR for age of
menopause <45 years: 1.20 and 1.38 vs. age of menopause
>53 and 45–53 years, respectively,—both non-significant)
(57). Of note, the WHS investigators did not find evidence
regarding the intermediary effect of interim CVD events during
follow-up in the (null) association between menopausal age
and AF.
DISCUSSION
AF affects about 1–2% of the total population. Prevalence
of AF increases with advancing age, rising to around 10%
in individuals older than 75 years (4, 58). Although age-
adjusted AF incidence and prevalence is larger among
men, women are older at the time of AF diagnosis and
have higher CHA2DS2-VASc scores. Moreover, women
with AF have worse quality of life and larger risk for
AF-associated adverse outcomes such as morality and
stroke (3, 59).
Epidemiological studies have highlighted gender differences
in epidemiology of AF. Elevated BMI seems to confer
a higher risk of AF among men. However, evidence
regarding sex differences in the association between
DM, elevated blood pressure, and dyslipidemia with AF
remains conflicting. While men with AF have larger
burden of coronary artery disease, women with AF tend
to have a larger prevalence of heart failure and valvular
heart disease.
When interpreting the results from epidemiological studies
of AF, several factors need to be taken into account. Firstly, the
true incidence and prevalence of AF are probably larger than
those indicated by the statistics from epidemiological studies as
prolonged electrocardiographic rhythm monitoring could lead
to identification of clinically silent AF among subjects who
present in sinus rhythm (60). Secondly, AF ascertainment in
epidemiological studies is challenging and there is a large room
for misclassification of AF status. The natural history of AF
is complex and the exact mechanisms and factors that govern
the clinical course of AF are uncertain. As AF progresses from
paroxysmal to persistent and permanent forms, the prevalence
of comorbidities as well as the accompanying risk factor burden
might change (61). Moreover, AF may change over time as the
AF-associated risk factors shift in prevalence and severity also
in response to primary and secondary prevention treatments
(8). These factors might affect the observed differences in
epidemiology and risk factors for AF between women and men.
Thirdly, observational studies may be subject to significant bias
and residual confounding from incompletely measured factors.
This may, in part, explain the observed differences between
women and men. Moreover, as pertinent to epidemiologic
research, the likelihood of false positive findings, especially
in the setting of multiple comparisons, should be considered.
The magnitude of the association, i.e., weak versus strong
associations, should be taken into account. Epidemiological
standards in the design, analysis, reporting, and interpretation
of studies need to be critically assessed. Finally, characteristics of
the epidemiological studies are central in interpreting the results.
Therefore, understanding the differences in risk factor profile
between women and men included in the studies, for example
in terms of the obesity or aging profile, is essential for making
solid inferences. Differences in the risk profile of women andmen
understudy might confound or influence interpretations.
Despite some suggestive sex-specific associations of risk
factors with AF, causality remains to be stablished. Genetic
studies improve our understanding of sexual dimorphism in
disease burden and susceptibility to risk factors. So far, sex-
specific genetic studies of AF are sparse. The recent large
meta-analysis of genome-wide association (GWA) studies for
AF identified 97 significant genetic loci which implicate genes
enriched within cardiac developmental, electrophysiological,
contractile and structural pathways (62). Sex-specific genetic
associations with AF, however, were not reported in this
large GWA study. Mendelian randomization approach uses
genetic variants as instrumental variables to establish potential
causality. This approach can be a strong alternative for
better understanding the sex-specific nature of the associations
of risk factors with AF. A recent large-scale Mendelian
randomization study has confirmed a causal relationship between
BMI and incident AF (63). However, sex differences were
not reported.
Besides observations from epidemiological and clinical
studies, to improve our understanding of sexual dimorphism
in AF, sufficiently large hypothesis-free GWA or candidate
gene studies with a priori, clearly defined hypotheses, as
well as well-powered Mendelian randomization studies
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are needed. Possible gene-gene and gene-environment
interactions should be considered. The discovered genetic
loci can be taken forward for further functional studies to
reveal plausible underlying sex-related pathophysiological
pathways in AF. Besides investigation of plausible underlying
pathophysiological mechanisms, appraisal of the suggested sex
differences in the association of several risk factors with AF
regarding their relevance to sex-specific prevention strategies
is warranted.
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